Advanced Search Close Search
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Biotechnology

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

  • By Atrium Therapeutics

SAN DIEGO, July 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on July 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of one non-executive individual newly hired by the Company.

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Medical Pharmaceuticals

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

  • By Atrium Therapeutics

SAN DIEGO, June 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on June 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of eight non-executive individuals newly hired by the Company.